Tesamorelin has been studied in people, and some studies measured sleep. In a small 2026 randomized trial, self-rated sleep quality did not differ significantly from placebo. This leaves open whether tesamorelin changes deep sleep or helps with insomnia.

Correction, November 17, 2026. The earlier version said tesamorelin had never been tested for sleep and suggested changing injection timing. This update includes human studies that measured or investigated sleep and removes the timing advice.

What the 2026 trial measured

A double-blind pilot trial primarily investigated cognition in adults aged 55 to 85. Participants were assigned to subcutaneous tesamorelin or placebo for 10 weeks. The final analysis included 22 people, 10 in the tesamorelin group and 12 in the placebo group. [1]

Participants completed the Pittsburgh Sleep Quality Index at baseline and weeks 6 and 10. The researchers found no statistically significant treatment effect and no significant difference between the groups in how the scores changed over time. The study was small and a self-rated questionnaire cannot answer whether tesamorelin alters deep sleep, which requires measuring sleep stages. [1]

What the FDA record and study registry show

Table 5 of the FDA medical review lists two earlier randomized, double-blind, placebo-controlled studies of subcutaneous tesamorelin. SLEEP/002 included 12 men and lasted seven days. SLEEP/005 included 82 people and lasted 14 days. The table establishes that the studies took place and describes their design. It does not give sleep results, so it cannot show whether tesamorelin helped.

A registered study of insomnia after traumatic brain injury planned to compare time in non-REM sleep on tesamorelin and placebo. A separate sleep-disordered breathing study planned to measure the apnea-hypopnea index. Both records are marked withdrawn and neither posts results.

The sleep-disordered breathing record was a planned observational study. Its withdrawal leaves the question it was designed to answer unresolved.

Does the hormone pathway explain sleep benefits?

Tesamorelin increases growth hormone secretion, as described in the FDA prescribing information. That hormone effect does not establish a sleep benefit. The label for EGRIFTA WR covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. It does not list a sleep indication.

Changes in self-rated sleep quality, measured sleep stages and nighttime breathing are different outcomes. The human evidence covered here does not establish a benefit for deep sleep, insomnia or sleep apnea.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.

References

  1. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci, 2026.